14 January 2021
EMA/594353/2020
EMEA/H/C/000713

Public statement

Sebivo

Withdrawal of the marketing authorisation in the European Union

On 5 November 2020, the marketing authorisation of Sebivo (telbivudine) ceased to be valid in the European Union (EU).

Novartis Europharm Limited confirmed that it discontinued the marketing of the product due to commercial reasons.

The European Public Assessment Report (EPAR) for Sebivo will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union